Participant flow

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) · Source last updated 2026-08-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Nirogacestat 150 mg by mouth, twice daily Nirogacestat oral tablet: Nirogacestat tablet

   id

   FG000

   title

   Double-Blind Phase - Nirogacestat

2. description

   Placebo by mouth, twice daily Placebo Oral Tablet: Sugar pill manufactured to mimic nirogacestat 50 mg tablet

   id

   FG001

   title

   Double-Blind Phase - Placebo

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         1

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      type

      Unqualified Clinical Progression

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      type

      Participant non-compliance

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Not treated

   5. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         11

      type

      Other reason

   6. reasons

      1. group Id

         FG000

         num Subjects

         36

      2. group Id

         FG001

         num Subjects

         23

      type

      Ongoing (still on treatment) pertains to treatment status at the time of the primary analysis

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         70

      2. group Id

         FG001

         num Subjects

         72

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         69

      2. group Id

         FG001

         num Subjects

         72

      type

      Treated (Safety Population)

   3. achievements

      1. group Id

         FG000

         num Subjects

         12

      2. group Id

         FG001

         num Subjects

         35

      comment

      Completed participants met the study endpoint. Information for completed and not completed pertains to treatment status at the time of the primary analysis. The open-label extension is ongoing.

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         58

      2. group Id

         FG001

         num Subjects

         37

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice